David Lodge
Overview
Explore the profile of David Lodge including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
47
Citations
995
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Collingridge G, Jane D, Lodge D
Neuropharmacology
. 2024 Jun;
:110046.
PMID: 38897382
No abstract available.
2.
Collingridge G, Evans R, Jane D, Lodge D
Neuropharmacology
. 2023 Jul;
:109650.
PMID: 37474350
No abstract available.
3.
Birnie M, Eapen A, Kershaw Y, Lodge D, Collingridge G, Conway-Campbell B, et al.
J Neuroendocrinol
. 2022 Sep;
34(10):e13194.
PMID: 36056546
Over 50% of depressed patients show hyperactivity of the hypothalamic-pituitary-adrenal (HPA) axis. Conventional therapy takes weeks to months to improve symptoms. Ketamine has rapid onset antidepressant effects. Yet its action...
4.
Frenguelli B, Lodge D, Rammes G, Collingridge G, Quack G, Jerecic J, et al.
Neuropharmacology
. 2021 Jul;
195:108633.
PMID: 34198024
No abstract available.
5.
Gunatilake S, Lodge D, Neville D, Jones T, Fogg C, Bassett P, et al.
BMJ Open Respir Res
. 2021 Jan;
8(1).
PMID: 33414260
Introduction: The prognosis of malignant pleural mesothelioma (MPM) is poor, with a median survival of 8-12 months. The ability to predict prognosis in MPM would help clinicians to make informed...
6.
Lodge D, Wallis A, Green B, Bishop L, Reynish D
Br J Hosp Med (Lond)
. 2020 Nov;
81(10):1.
PMID: 33135919
No abstract available.
7.
Kang H, Park P, Han M, Tidball P, Georgiou J, Bortolotto Z, et al.
Brain Neurosci Adv
. 2020 Oct;
4:2398212820957847.
PMID: 33088919
The ketamine metabolite (2,6)-hydroxynorketamine has been proposed to have rapid and persistent antidepressant actions in rodents, but its mechanism of action is controversial. We have compared the ability of ()-ketamine...
8.
Jones M, Heiden E, Fogg C, Meredith P, Smith G, Sayer N, et al.
JMIR Res Protoc
. 2020 Jul;
9(7):e15437.
PMID: 32706740
Background: Respiratory rate (RR) is the most sensitive physiological observation to predict clinical deterioration on hospital wards, and poor clinical monitoring has been highlighted as a primary contributor to avoidable...
9.
Wallach J, Colestock T, Agramunt J, Claydon M, Dybek M, Filemban N, et al.
Eur J Pharmacol
. 2019 Jun;
857:172427.
PMID: 31152702
1,2-Diarylethylamines represent a class of molecules that have shown potential in the treatment of pain, epilepsy, neurodegenerative disease and depression. Examples include lefetamine, remacemide, and lanicemine. Recently, several 1,2-diarylethylamines including...
10.
Wood C, Wafford K, McCarthy A, Hewes N, Shanks E, Lodge D, et al.
Neuropharmacology
. 2018 Jul;
140:246-259.
PMID: 30005976
Group II metabotropic glutamate receptors (mGluR2 and mGluR3) are implicated in a number of psychiatric disorders. They also control sleep-wake architecture and may offer novel therapeutic targets. However, the roles...